Publicaciones (71) Publicaciones de ANTONIO LIRAS MARTÍN

2023

  1. La magia de las proteasas: De un factor v procoagulante y anticoagulante a un tratamiento equitativo de su deficiencia hereditaria

    Investigaciones DACIU 2022-2023: Una publicación que refleja los trabajos realizados por los participantes en el programa DACIU en su primera edición (Avanza), pp. 73-80

  2. The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

    International Journal of Molecular Sciences, Vol. 24, Núm. 7

  3. Therapeutic potential of fetal liver cell transplantation in hemophilia A mice

    Haematologica, Vol. 108, Núm. 6, pp. 1544-1554

  4. Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas)

    Thrombosis Research, Vol. 231, pp. 99-111

2022

  1. Development and Characterization of a Factor V‐Deficient CRISPR Cell Model for the Correction of Mutations

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models

    Frontiers in Veterinary Science, Vol. 9

  3. The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V

    International journal of molecular sciences, Vol. 23, Núm. 15

2021

  1. Cell therapy for factor V deficiency: An approach based on human decidua mesenchymal stem cells

    Biomedicine and Pharmacotherapy, Vol. 142

  2. Gene and Cell Therapy in Dental Tissue Regeneration

    Human Tooth and Developmental Dental Defects - Compositional and Genetic Implications

  3. Gene therapy in hemophilia: Recent advances

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

  4. High mutational heterogeneity, and new mutations in the human coagulation factor v gene. Future perspectives for factor v deficiency using recombinant and advanced therapies

    International Journal of Molecular Sciences, Vol. 22, Núm. 18

2019

  1. Dental management of patients with haemophilia in the era of recombinant treatments: Increased efficacy and decreased clinical risk

    BMJ Case Reports, Vol. 12, Núm. 4

2018

  1. Searching for a Cell-Based Therapeutic Tool for Haemophilia A within the Embryonic/Foetal Liver and the Aorta-Gonads-Mesonephros Region

    Thrombosis and Haemostasis, Vol. 118, Núm. 8, pp. 1370-1381

2016

  1. Preliminary study on non-viral transfection of F9 (factor IX) gene by nucleofection in human adipose-derived mesenchymal stem cells

    PeerJ, Vol. 2016, Núm. 4

2015

  1. Biological therapies for inherited diseases: Social and bioethical considerations. Hemophilia as an example

    Expert Opinion on Biological Therapy, Vol. 15, Núm. 5, pp. 713-722

2013

  1. Treatment for hemophilia: Recombinant versus plasma-derived coagulation factors-controversy and debate forever? An ethical medical challenge?

    Expert Review of Hematology, Vol. 6, Núm. 5, pp. 489-492

2012

  1. Advanced therapies for hemophilia: Reality or fantasy?

    Expert Review of Hematology, Vol. 5, Núm. 3, pp. 245-247

  2. Advanced therapies for the treatment of hemophilia: Future perspectives

    Orphanet Journal of Rare Diseases, Vol. 7, Núm. 1

  3. Cartilage restoration in haemophilia: Advanced therapies

    Haemophilia, Vol. 18, Núm. 5, pp. 672-679

2011

  1. Induced human pluripotent stem cells and advanced therapies: Future perspectives for the treatment of haemophilia?

    Thrombosis Research, Vol. 128, Núm. 1, pp. 8-13